# Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

> **NCT03483324** · PHASE1 · COMPLETED · sponsor: **Angiocrine Bioscience** · enrollment: 10 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Myelodysplastic Syndromes
- Other Acute Leukemias

## Interventions

- **BIOLOGICAL:** Unmanipulated Umbilical Cord Blood (UCB)
- **BIOLOGICAL:** AB-110

## Key facts

- **NCT ID:** NCT03483324
- **Lead sponsor:** Angiocrine Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2020-12-21
- **Final completion:** 2022-01-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483324, "Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03483324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*